ENGNW — enGene Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1980845 ·
Quebec, Canada
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jul 2026 | 0 | — | -34,014,000 | -32,501,000 | 288,322,000 | 41,025,000 | 58,032,000 |
| Apr 2026 | 0 | — | -31,968,000 | -30,227,000 | 307,524,000 | 29,827,000 | 52,356,000 |
| Jan 2026 | 0 | — | -31,185,000 | -29,752,000 | 337,113,000 | 36,613,000 | 55,567,000 |
| Oct 2025 | 0 | — | -39,481,000 | -37,880,000 | 221,468,000 | 50,152,000 | 53,758,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-103,309,000
Investing CF
$-32,038,000
Financing CF
$143,748,000
CapEx
$-1,392,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-09-13
Balance + Analyst (yfinance extras)
Retained Earnings
$-464,512,000
Inventory
—
Receivables
$975,000
ST Investments
$225,295,000
EBIT TTM
$-127,787,000
Pretax Income TTM
$-130,857,000
Interest Exp TTM
$3,070,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Oct 2025 | 0 | -123,165,000 | -117,302,000 | 221,468,000 | 53,758,000 | 167,710,000 | -99,239,000 |
| Oct 2024 | 0 | -62,297,000 | -55,142,000 | 311,173,000 | 38,561,000 | 272,612,000 | -48,281,000 |
| Oct 2023 | 0 | -26,060,000 | -99,917,000 | 86,959,000 | 14,473,000 | 72,486,000 | -24,743,000 |
| Oct 2022 | 0 | -19,427,000 | -24,462,000 | 23,909,000 | 47,405,000 | -23,496,000 | -17,592,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $224.15B | $414.61 | — |
| GILD | GILEAD SCIENCES, INC. | $187.15B | $150.93 | — |
| MRNA | Moderna, Inc. | $79.40B | $198.88 | — |
| ARGX | ARGENX SE | $59.67B | $959.49 | — |
| RVMD | Revolution Medicines, Inc. | $43.93B | $204.97 | — |
News headlines (Yahoo Finance, 1h cache)
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
2026-07-16 12:00 · Yahoo
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-09-08 11:30 · Yahoo
enGene to Participate in Upcoming Investor Conferences
2026-09-01 12:30 · Yahoo
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
2026-08-13 15:07 · Yahoo
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
2026-08-04 12:00 · Yahoo
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
2026-07-15 13:00 · Yahoo
Neumora depression drug fails; EnGene to cut 50% of staff
2026-06-16 09:08 · Yahoo
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-06-15 13:00 · Yahoo
A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations
2026-05-11 01:11 · Yahoo
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
2026-05-08 23:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.